U.S. pharma giant copyright scrapped two experimental weight loss tablets past calendar year—a the moment-day-to-day capsule, lotiglipron, resulting from elevated liver enzymes as well as a twice-every day tablet, danuglipron, resulting from robust Unintended effects—but CEO Albert Bourla has explained the company is set to “Engage in and ear